WO2006055635A3 - Compositions et methodes de modification de la signalisation autocrine wnt - Google Patents

Compositions et methodes de modification de la signalisation autocrine wnt Download PDF

Info

Publication number
WO2006055635A3
WO2006055635A3 PCT/US2005/041531 US2005041531W WO2006055635A3 WO 2006055635 A3 WO2006055635 A3 WO 2006055635A3 US 2005041531 W US2005041531 W US 2005041531W WO 2006055635 A3 WO2006055635 A3 WO 2006055635A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
wnt
compositions
signaling
autocrine signaling
Prior art date
Application number
PCT/US2005/041531
Other languages
English (en)
Other versions
WO2006055635A9 (fr
WO2006055635A2 (fr
Inventor
Anna Bafico
Stuart Aaronson
Original Assignee
Sinai School Medicine
Anna Bafico
Stuart Aaronson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine, Anna Bafico, Stuart Aaronson filed Critical Sinai School Medicine
Priority to US11/719,327 priority Critical patent/US8809287B2/en
Priority to JP2007541463A priority patent/JP2008520583A/ja
Publication of WO2006055635A2 publication Critical patent/WO2006055635A2/fr
Publication of WO2006055635A9 publication Critical patent/WO2006055635A9/fr
Publication of WO2006055635A3 publication Critical patent/WO2006055635A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés, et des méthodes de traitement de cancers dans lesquelles la voie de signalisation canonique Wnt autocrine est activée. L'invention concerne en particulier une méthode pouvant inhiber la croissance d'une cellule tumorale ou sensibiliser une cellule cancéreuse au traitement, laquelle méthode consiste à placer la cellule tumorale au contact d'un composé qui modifie la signalisation Wnt et qui peut être un antagoniste de Wnt, un antagoniste du récepteur de Wnt ou leur combinaison.
PCT/US2005/041531 2004-11-15 2005-11-15 Compositions et methodes de modification de la signalisation autocrine wnt WO2006055635A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/719,327 US8809287B2 (en) 2004-11-15 2005-11-15 Compositions and methods for altering Wnt autocrine signaling
JP2007541463A JP2008520583A (ja) 2004-11-15 2005-11-15 Ｗｎｔ自己分泌シグナル伝達を改変するための組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62797704P 2004-11-15 2004-11-15
US60/627,977 2004-11-15

Publications (3)

Publication Number Publication Date
WO2006055635A2 WO2006055635A2 (fr) 2006-05-26
WO2006055635A9 WO2006055635A9 (fr) 2006-08-24
WO2006055635A3 true WO2006055635A3 (fr) 2007-03-29

Family

ID=36407727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041531 WO2006055635A2 (fr) 2004-11-15 2005-11-15 Compositions et methodes de modification de la signalisation autocrine wnt

Country Status (3)

Country Link
US (1) US8809287B2 (fr)
JP (1) JP2008520583A (fr)
WO (1) WO2006055635A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (ja) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
WO2007140410A2 (fr) * 2006-05-30 2007-12-06 Van Andel Research Institute Récepteur 6 des lipoprotéines à faible densité (lrp6) utilisé en tant que marqueur de cellules souches mammaires et procédés associés
CA2662041A1 (fr) 2006-09-08 2008-03-13 Genentech, Inc. Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt
JP5027481B2 (ja) * 2006-11-06 2012-09-19 株式会社日立製作所 Ｉｃタグ
EP2209491B1 (fr) * 2007-11-02 2015-10-28 Novartis AG Molécules et méthodes de modulation de la protéine 6 liée au récepteur des lipoprotéines de basse densité (lrp6)
EA201000673A1 (ru) * 2007-11-05 2011-04-29 Новартис Аг СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
WO2009064944A2 (fr) * 2007-11-16 2009-05-22 Nuvelo, Inc. Anticorps dirigés contre lrp6
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US20140113006A1 (en) * 2009-04-17 2014-04-24 Mount Sinai School Of Medicine Methods of determining whether the wnt signaling pathway is upregulated in a tumor
WO2011004379A1 (fr) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions et méthodes de traitement du cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP4234698A3 (fr) 2010-05-06 2023-11-08 Novartis AG Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
WO2012109540A1 (fr) * 2011-02-10 2012-08-16 Fox Chase Cancer Center Procédés d'induction de sénescence de cellules cancéreuses épithéliales
CN102266561B (zh) * 2011-07-14 2012-10-03 南京农业大学 Wnt/β-catenin信号通路抑制剂在制备促进细胞凋亡的药物中的应用
EP3252075A1 (fr) 2011-11-04 2017-12-06 Novartis AG Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
EP2911691B1 (fr) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3859752A (en) 1973-06-01 1975-01-14 Marvin Glass & Associates Toy vehicle having means for canting wheels on collision
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4274149A (en) 1980-02-19 1981-06-16 Flanagan Charles E Binocular device for displaying elapsed time in the field of view
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
WO1992022635A1 (fr) 1991-06-05 1992-12-23 University Of Connecticut Apport cible de genes codant des proteines secretoires
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5679582A (en) 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6020141A (en) 1996-05-09 2000-02-01 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization
WO1999050655A1 (fr) 1998-03-30 1999-10-07 Cell Therapeutics, Inc. Methodes de separation et de detection
JP4095895B2 (ja) * 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWANO Y. ET AL.: "Secreted antagonists of the Wnt signalling pathway", JOURNAL OF CELL SCI., vol. 116, 2003, pages 2627 - 2634, XP002321050 *
MELKONYAN ET AL.: "SARPs: A family of secreted apoptosis-related proteins", PROC. NATL. ACAD. SCI. USA, vol. 94, December 1997 (1997-12-01), pages 13636 - 13641, XP002057810 *

Also Published As

Publication number Publication date
WO2006055635A9 (fr) 2006-08-24
US20090163407A1 (en) 2009-06-25
JP2008520583A (ja) 2008-06-19
WO2006055635A2 (fr) 2006-05-26
US8809287B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
WO2006055635A3 (fr) Compositions et methodes de modification de la signalisation autocrine wnt
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2005117867A3 (fr) Heterocycles monocycliques commes inhibiteurs de kinases
MY153243A (en) Compound for inhibiting mitotic progression
WO2007087245A3 (fr) Inhibition de la tyrosine kinase ret
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2007123892A3 (fr) Inhibiteurs raf et leurs utilisations
EP1549144A4 (fr) Methodes de traitement du cancer par inhibition de la signalisation de wnt
WO2007076348A3 (fr) Inhibiteurs azaindoliques des kinases aurora
WO2006113703A3 (fr) Derives de carboline utiles dans le traitement du cancer
WO2009049214A3 (fr) Inhibition et traitement d'une métastase du cancer de la prostate
WO2008112199A8 (fr) Procédé d'inhibition de la topoisomérase ii
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
WO2008076949A3 (fr) Dérivés de quinazoline et procédés de traitement
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
WO2010042933A3 (fr) Inhibition et traitement des métastases du cancer de la prostate
WO2007081966A3 (fr) Petites molécules pour traiter un cancer et des troubles de prolifération cellulaire anormale
HK1155664A1 (en) Treatment of metastasized tumors
WO2005025515A3 (fr) Inhibiteurs de la voie des proteasomes et methodes associees
WO2007115805A3 (fr) Inhibiteurs de la kinase aurora
WO2007124369A3 (fr) Procédé d'inhibition de la kinase de c kit
WO2009121042A8 (fr) Dérivés de quinazoline et procédés de traitement
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2004058705A3 (fr) Inhibiteurs de ccxckr2 d'expression tumorale humaine
WO2006119148A3 (fr) Inhibiteurs specifiques contre la tyrosine du recepteur du facteur de croissance des keratinocytes utiles pour prevenir les metastases cancereuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007541463

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11719327

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 05849394

Country of ref document: EP

Kind code of ref document: A2